187 related articles for article (PubMed ID: 31983515)
1. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
[TBL] [Abstract][Full Text] [Related]
4. Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.
Tokunaga H; Takahashi F; Yamamoto H; Honda T; Watanabe T; Shoji T; Sugiyama T; Yamada H; Tando T; Yoshinaga K; Kagabu S; Otsuki T; Kin S; Yokoyama Y; Wagatsuma S; Sato K; Sato H; Oishi T; Yoshida Y; Hayasaka T; Matsui T; Imai N; Nishigori H; Shimokawa H; Yaegashi N; Watanabe Y
Int J Clin Oncol; 2017 Jun; 22(3):541-547. PubMed ID: 28188392
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
Hensley ML; Ishill N; Soslow R; Larkin J; Abu-Rustum N; Sabbatini P; Konner J; Tew W; Spriggs D; Aghajanian CA
Gynecol Oncol; 2009 Mar; 112(3):563-7. PubMed ID: 19135708
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Hensley ML; Miller A; O'Malley DM; Mannel RS; Behbakht K; Bakkum-Gamez JN; Michael H
J Clin Oncol; 2015 Apr; 33(10):1180-5. PubMed ID: 25713428
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
Chae SH; Shim SH; Chang M; Choi AY; Kang GG; Lee SJ; Kim SN
Gynecol Oncol; 2019 Sep; 154(3):638-650. PubMed ID: 31307664
[TBL] [Abstract][Full Text] [Related]
8. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003.
Ayhan A; Gungorduk K; Khatib G; Fırat Cüylan Z; Boran N; Gökçü M; Çelik H; Özgül N; Akbayir Ö; Şimşek T; Bakay A; Faruk Köse M; Tunç M; Küçükgöz Güleç Ü; Koç S; Kuşçu E; Vardar MA; Akilli H; Taskiran C; Mutlu Meydanlı M
Curr Probl Cancer; 2021 Oct; 45(5):100712. PubMed ID: 33685725
[TBL] [Abstract][Full Text] [Related]
12. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis.
Ijaz I; Shahzad MN; Hosseinifard H; Liu S; Sefidan MO; Kahloon LE; Imani S; Hua Z; Zhang YQ
Cancer Med; 2023 Jul; 12(13):13894-13911. PubMed ID: 37081717
[TBL] [Abstract][Full Text] [Related]
14. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.
Chantharasamee J; Wong K; Potivongsajarn P; Qorbani A; Motamed N; Brackert S; Cohen J; Chmielowski B; Kalbasi A; Rao J; Nelson S; Singh A
Cancer Med; 2022 Aug; 11(15):2906-2912. PubMed ID: 35307963
[TBL] [Abstract][Full Text] [Related]
16. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Takano T; Niikura H; Ito K; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Tokunaga H; Kaiho-Sakuma M; Shiga N; Nagai T; Tanaka S; Otsuki A; Kurosawa H; Shigeta S; Tsuji K; Yamaguchi T; Yaegashi N
Int J Clin Oncol; 2014 Oct; 19(5):897-905. PubMed ID: 24149774
[TBL] [Abstract][Full Text] [Related]
17. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
18. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
[TBL] [Abstract][Full Text] [Related]
20. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
